Pace Corp., Boehringer Mannheim GmbH deal

The German pharma company received a six-month exclusive option to PACL's technology for its cardiac diagnostic test based on glycogen phosphorylase BB (GPBB). PACL (Richmond Hill, Ontario) received an undisclosed option payment and will receive royalties. PACL anticipates filing a 510(k) on the product by year end. ...